Where a young woman puts down roots may quietly influence her odds of developing cervical cancer. A sweeping new analysis finds that while national rates have dropped since the HPV vaccine arrived on the scene, the size of that decline changes dramatically from one state line to the next.
The peer-reviewed study looked at cervical cancer incidence in women ages 20 to 31 before the HPV vaccine era, from 2000 to 2005, and during the vaccine era, from 2016 to 2021, using data from the U.S. Cancer Statistics database. According to the Journal of the National Cancer Institute, incidence nationwide fell about 27%, from 5.1 to 3.7 cases per 100,000 across those time periods.
Big Drops in Some Places, Barely a Dent in Others
The American Cancer Society reports that declines topped 50% in Washington, D.C., Rhode Island, Michigan and Hawaii. Another 28 states saw more modest reductions of about 15% to 50%. Ten states saw only small decreases.
As the American Cancer Society noted, several states, including Vermont, West Virginia, Idaho, Arkansas and Alabama, showed little to no measurable progress at all. In other words, your risk can look very different depending on which side of a border you live on.
Beneath those headline numbers, the analysis found a tight link between HPV vaccination and falling cancer rates. Every 10 percentage point increase in HPV vaccination coverage was associated with an estimated 11.5% reduction in relative risk, after adjusting for screening patterns. The researchers drew vaccination figures from the National Immunization Survey–Teen and accounted for screening using Behavioral Risk Factor Surveillance System data, according to the Journal of the National Cancer Institute.
Vaccination Gains Are Slowing Just When They Matter Most
Nationally, HPV vaccination uptake has stalled instead of surging in ways that might close those state-by-state gaps. The 2024 National Immunization Survey–Teen from the CDC found that about 78.2% of adolescents had received at least one HPV dose and 62.9% were up to date with the full series. Coverage was notably lower in nonmetropolitan areas.
Leaders at the American Cancer Society say that uneven landscape is also an opportunity. In a statement, they argued that the study underscores how the benefits of one of the most effective and highly affordable cancer prevention tools are still not shared equally, pointing to room for targeted outreach and policy changes.
What This Means for You
Clinics and health systems emphasize that the HPV shot remains a workhorse of cancer prevention. The Cleveland Clinic notes that HPV vaccination protects against cancers caused by the virus and is recommended for people ages 9 through 45.
As Cleveland.com reported, the new analysis reinforces that when a community gets vaccinated, the whole population benefits. Routine cervical cancer screening still matters, even for those who are vaccinated.
Public health experts boil the message down to something simple: vaccines and screening work, but only when they reach everyone. For states lagging behind, the study offers a clear checklist for catching up: raise vaccination rates, expand access to screening and track progress closely at the local level.
